Co-Diagnostics, Inc.
CODX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.18 | -0.01 | 0.04 | -0.35 |
| FCF Yield | -131.43% | -60.07% | 6.48% | 15.67% |
| EV / EBITDA | -0.57 | -0.65 | -5.50 | 3.65 |
| Quality | ||||
| ROIC | -69.69% | -43.79% | -7.31% | 25.10% |
| Gross Margin | 74.48% | 38.57% | 83.98% | 88.18% |
| Cash Conversion Ratio | 0.77 | 0.62 | -0.46 | 1.12 |
| Growth | ||||
| Revenue 3-Year CAGR | -51.45% | -58.87% | -22.86% | 669.33% |
| Free Cash Flow Growth | -27.54% | -556.06% | -87.28% | 47.54% |
| Safety | ||||
| Net Debt / EBITDA | 0.02 | 0.29 | 2.19 | -1.91 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.93 | 2.51 | 1.03 | 5.78 |
| Cash Conversion Cycle | -799.21 | 33.66 | 347.81 | 122.03 |